Bookmark and Share

ADVAGRAF Drug Information Page

Updated 08/09/2010 12:50:37 AM

ProductSourceDateLinkData
ADVAGRAFMHRA2010-2-8ADVAGRAF-MHRA-2010-2-8MHRA Drug Updates: Tacrolimus: new oral liquid (Modigraf); formulations not interchangeable without careful therapeutic monitoring. Problem with postal delivery of Yellow Cards. Suspected adverse reactions to flu antivirals and vaccines confirm recognised safety profile. Orlistat safety update. Nicotine replacement therapy and harm reduction. Sibutramine: suspension of EU licenses recommended as evidence indicates risks outweigh benefits. Off-label intraocular use of recombinant tissue plasminogen activator: risk of intraocular lens opacification.
ADVAGRAFMHRA2009-1-6ADVAGRAF-MHRA-2009-1-6MHRA has issued drug updates: Piperacillin/tazobactam: compatibility of generics differs from brand leader (Tazocin) Temsirolimus: severe hypersensitivity reactions during infusion Tacrolimus (Advagraf and Prograf): risk of serious medication errors
ADVAGRAFMHRA2008-12-3ADVAGRAF-MHRA-2008-12-3MHRA has issued drug updates: Nitrous oxide: neurological and haematological toxic effects, especially with prolonged use Rituximab and efalizumab: progressive multifocal leukoencephalopathy Conventional (typical) antipsychotics: increased mortality in dementia Prograf and Advagraf (tacrolimus): serious medication errors Norfloxacin: restricted use in urinary infections Hedrin: keep treated hair away from sources of fire Melanotan: an unlicensed medicine, the risks of which are unknown Tigecycline reformulation affects compatibility: correction

Joining this website will allow you to recieve emails about any pharmaceutial you are interested in or you can search for other pharmaceuticals on this website. Joining should only take 2 minutes.